Clostridium difficile Infection, Colorado and the Northwestern United States, 2007

Jennifer L. Kuntz, Eric S. Johnson, Marsha A. Raebel, Amanda F. Petrik, Xiuhai Yang, Micah L. Thorp, Steven J. Spindel, Nancy Neil, and David H. Smith

To determine the incidence of Clostridium difficile infection during 2007, we examined infection in adult inpatient and outpatient members of a managed-care organization. Incidence was 14.9 C. difficile infections per 10,000 patient-years. Extrapolating this rate to US adults, we estimate that 284,875 C. difficile infections occurred during 2007.

Clostridium difficile infection is a major source of illness in the United States (1). Population-based estimates of its incidence tend to include only subsets of infections defined by the setting of C. difficile acquisition (2–4) or are from patient populations outside the United States (5–9). These studies (2–9) offer useful data for control measures but do not help clinicians and policy makers understand the population-based incidence of C. difficile infection. To determine the incidence of C. difficile infection during 2007, we estimated the incidence of C. difficile infection among members of 2 Kaiser Permanente health plans and extrapolated our incidence estimate to the US adult population.

The Study

We identified C. difficile infections during January 1–December 31, 2007, among Kaiser Permanente Colorado and Kaiser Permanente Northwest members ≥20 years of age. The health plans had a combined membership of ≈900,000 on any given day during 2007. We collected patient membership, demographic, and clinical data using electronic databases. C. difficile infections were identified through International Classification of Diseases, 9th Revision (ICD-9), code 008.45 (“Intestinal infection due to C. difficile”) recorded during an inpatient or outpatient health care visit or a positive C. difficile toxin test result. To increase the likelihood that cases were symptomatic, we further required that positive toxin test results be associated with dispensation of metronidazole or vancomycin in the outpatient pharmacy in the 7 days before or after a positive test result. Specimens were reported as negative or positive on the basis of results from a Meridian Premier Toxin A/B enzyme immunoassay (Meridian Bioscience, Cincinnati, OH, USA).

A C. difficile infection was considered incident if the patient did not have a history of a C. difficile diagnosis, a positive toxin test result, or an outpatient prescription for vancomycin or metronidazole in the previous 180 days. To ensure cases were incident and to collect baseline characteristics, patients with C. difficile infections were required to have continuous membership and prescription drug coverage for 1 year before the date of C. difficile infection.

We calculated the total incidence of C. difficile infection as the number of incident cases among persons ≥20 years of age per 10,000 person-years of observation. Age- and sex-specific incidence rates were also calculated. A patient could have had >1 incident C. difficile infections if they occurred >180 days apart. Denominator data were based on duration of membership for persons ≥20 years of age with continuous membership and prescription drug coverage for 1 year before July 31, 2007. To project the national incidence of C. difficile infection, we applied pooled, age-specific incidence, and sex-specific incidence estimates to the 2007 US population. As a sensitivity analysis, we also provided the incidence projection for US whites because earlier surveys of members showed a predominantly (90%) white membership, and race data were unavailable for a substantial proportion of members.

We identified 870 incident C. difficile infections among members ≥20 years of age in 2007; a total of 473 (54%) of 870 C. difficile infections were identified among outpatients. Overall incidence was 14.9 C. difficile infections per 10,000 patient-years; age-specific incidence rates ranged from 2.4 infections per 10,000 patient-years for men 20–29 years of age to 87.1 infections per 10,000 patient-years for men ≥80 years of age (Table). On the basis of these age- and sex-specific rates, we estimated that 284,875 C. difficile infections occurred among the overall

1This research was presented as a poster at the 2011 HMO Research Network Conference, Boston, Massachusetts, USA, on March 23, 2011, and at the 2011 International Conference on Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Chicago, Illinois, USA, on August 16, 2011.
US population ≥20 years of age. We also estimated that 241,815 infections occurred among US whites (Table).

Conclusions

Our study identified new infections among this managed care population in 2007 and estimated the occurrence of new infections within the US population. Our approach differed from those of previous reports that were based on individual medical institutions, hospital discharge databases, or voluntary surveillance in targeted populations and geographic areas (10–13). We differentiated between incident and prevalent infections. Identification of incident infections is needed to understand the causes and predictors of infection and to develop clinical interventions to prevent infection. Because we also identified *Clostridium difficile* infection among inpatients and outpatients, our estimates more fully account for total *C. difficile* infection and provide a foundation for studying the potential spread of *C. difficile* between ambulatory and hospitalized persons.

Although different objectives and methods make direct comparisons difficult, we found that the incidence of *C. difficile* infection among the Kaiser Permanente population studied (14.9 infections/10,000 patient-years) did not differ substantially from the 11.2 *C. difficile*-associated hospitalizations among adults per 10,000 population identified in the 2005 Nationwide Inpatient Sample (14). Our estimate of 240,000–285,000 incident *C. difficile* infections in the US adult population in 2007 is comparable with the results of an extrapolation by Campbell et al., which found that on the basis of health care–facility surveillance data, 333,000 initial and 145,000 recurrent *C. difficile* infections might have occurred nationwide in 2006 (15). Although previous reports of inpatient encounters resulting from *C. difficile* infection or total *C. difficile* infections are needed to describe the impact of *C. difficile* infection on the health care system, our identification of infections in inpatient and outpatient health care settings may provide a more accurate estimate of *C. difficile* infection incidence.

Many discharge databases do not include longitudinal patient identifiers; even though these databases can identify diagnoses during hospitalizations, they cannot link hospitalizations to specific patients. Thus, multiple hospitalizations for recurrent or refractory *C. difficile* infection would count as multiple infections, whereas we followed-up patients over time to ensure that only incident infections were counted. Furthermore, although we relied on ICD-9 codes to identify cases among inpatients, we also used *C. difficile* toxin tests, treatment for *C. difficile* infection, and *C. difficile*–related health care encounters to identify infections in outpatients. We could have missed infections in inpatients if the ICD-9 code for *C. difficile* was absent; however, our use of toxin test results and pharmacy dispensing records likely resulted in more accurate and complete identification of *C. difficile* infection among outpatients. In fact, we found that >95% of patients with positive toxin test result had a treatment-dispensing or ICD-9 code for *C. difficile* infection.

Our data might overestimate or underestimate the incidence of *C. difficile* infection or affect the interpretation of our results in 4 ways. First, our population was predominantly white. Although we are unaware of any evidence that *C. difficile* infections occur disproportionately by race or ethnicity, we projected our incidence rate to the entire and white-only US populations to acknowledge the distribution of race in the study population. Second, our insured population could be healthier than the US population. Third, Kaiser Permanente has policies and procedures that promote judicious prescription of antimicrobial drugs and effective infection control and prevention. Collectively, a healthy population, health plan

### Table. Incidence of *Clostridium difficile* infection among members ≥20 years of age of Kaiser Permanente Colorado and Northwest, USA, with projections to US white and US total populations, 2007*<sup>7</sup>

| Sex/age, y | Kaiser Permanente populations | Projected no. US infections |
|------------|--------------------------------|-----------------------------|
|            | Incident infections, no. | Incidence rate* (SE) | Whites | Total |
| Female     |                                |                            |        |       |
| 20–29      | 12                             | 3.1 (0.91)                 | 4,920  | 6,383 |
| 30–39      | 31                             | 6.1 (1.09)                 | 9,399  | 12,186|
| 40–49      | 45                             | 7.2 (1.1)                  | 13,079 | 16,386|
| 50–59      | 80                             | 11.5 (1.3)                 | 18,892 | 23,046|
| 60–69      | 96                             | 21.3 (2.2)                 | 23,340 | 27,681|
| 70–79      | 119                            | 42.0 (3.8)                 | 32,141 | 37,503|
| ≥80        | 140                            | 79.5 (6.7)                 | 42,559 | 48,016|
| Male       |                                |                            |        |       |
| 20–29      | 8                              | 2.4 (0.85)                 | 3,969  | 5,009 |
| 30–39      | 18                             | 3.9 (0.93)                 | 6,318  | 7,871 |
| 40–49      | 29                             | 5.2 (0.96)                 | 9,274  | 11,321|
| 50–59      | 62                             | 10.1 (1.3)                 | 16,242 | 19,359|
| 60–69      | 67                             | 16.7 (2.0)                 | 16,747 | 19,359|
| 70–79      | 73                             | 31.1 (3.6)                 | 18,994 | 21,780|
| ≥80        | 90                             | 87.1 (9.2)                 | 25,941 | 28,980|
| All        | 870                            | 14.9 (0.5)                 | 241,815| 284,875|

*Per 10,000 patient-years
policies, and clinician awareness might result in fewer *C. difficile* infections among this population than is observed in other health care settings. Fourth, toxin tests are imperfect, potentially leading to overestimation of incidence.

Our study provides population-level estimates of *C. difficile* infection in inpatients and outpatients. However, more efficient and timely methods for identifying and reporting *C. difficile* infection are needed to further improve understanding of the epidemiology of *C. difficile* infection and the interventions necessary to prevent them.

Acknowledgment

We gratefully acknowledge Karen Glenn for her analytic efforts and expertise.

This study was funded by Sanofi Pasteur.

Dr Kuntz is an assistant investigator at the Kaiser Permanente Northwest Center for Health Research in Portland, Oregon. Her primary research interests are the epidemiology of *C. difficile* infection and drug safety and comparative effectiveness research.

References

1. Johnson S, Gerding DN. *Clostridium difficile*-associated diarrhoea. Clin Infect Dis. 1998;26:1027–34. http://dx.doi.org/10.1086/520276
2. Kutty PK, Woods CW, Sena AC, Benoit SR, Naggie S, Frederick J, et al. Risk factors for and estimated incidence of community-associated *Clostridium difficile* infection, North Carolina, USA. Emerg Infect Dis. 2010;16:197–204.
3. Lambert PJ, Dyck M, Thompson LH, Hammond GW. Population-based surveillance of *Clostridium difficile* infection in Manitoba, Canada, by using interim surveillance definitions. Infect Control Hosp Epidemiol. 2009;30:945–51. http://dx.doi.org/10.1086/605719
4. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of *Clostridium difficile*-associated disease. Infect Control Hosp Epidemiol. 2007;28:140–5. http://dx.doi.org/10.1086/511798
5. Dial S, Delaney JA, Barkun AN, Suisse S. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. JAMA. 2005;294:2989–95. http://dx.doi.org/10.1001/jama.294.23.2989
6. Noren T, Akerlund T, Back E, Sjoberg L, Persson I, Alikronsson I, et al. Molecular epidemiology of hospital-associated and community-acquired *Clostridium difficile* infection in a Swedish county. J Clin Microbiol. 2004;42:3635–43. http://dx.doi.org/10.1128/JCM.42.8.3635-3643.2004
7. Karlstrom O, Fryklund B, Tullus K, Burman L-G. A prospective nationwide study of *Clostridium difficile*-associated diarrhea in Sweden. The Swedish *C. difficile* Study Group. Clin Infect Dis. 1998;26:141–5.
8. Burekhardt F, Friedrich A, Beier D, Eckmanns T. *Clostridium difficile* surveillance trends, Saxony, Germany. Emerg Infect Dis. 2008;14:691–2. http://dx.doi.org/10.3201/eid1404.071023
9. Lamberts ML, Mertens K, Ramboer I, Delmee M, Suetens C. Nationwide prospective surveillance of *Clostridium difficile* infections in hospitals in Belgium, July 2007–June 2008. Euro Surveill. 2009;14:2–4.
10. Bauer MP, Goorhuis A, Koster T, Numan-Ruberg SC, Hagen EC, Debast SB, et al. Community-onset *Clostridium difficile*-associated diarrhoea not associated with antibiotic usage—two case reports with review of the changing epidemiology of *Clostridium difficile*-associated diarrhoea. Neth J Med. 2008;66:207–11.
11. Centers for Disease Control and Prevention. Severe *Clostridium difficile*-associated disease in populations previously at low risk—four states, 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1201–5.
12. Centers for Disease Control and Prevention. Surveillance for community-associated *Clostridium difficile*—Connecticut, 2006. MMWR Morb Mortal Wkly Rep. 2008;57:340–3.
13. Dubberke ER, Butler AM, Yokoe DS, Mayer J, Hota B, Mangino IE, et al. Multicenter study of *Clostridium difficile* infection rates from 2000 to 2006. Infect Control Hosp Epidemiol. 2010;31:1030–7. http://dx.doi.org/10.1086/656245
14. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult *Clostridium difficile*–related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14:929–31. http://dx.doi.org/10.3201/eid1406.071447
15. Campbell RJ, Giljahn L, Machesky K, Cibulskas-White K, Lane LM, Porter K, et al. *Clostridium difficile* infection in Ohio hospitals and nursing homes during 2006. Infect Control Hosp Epidemiol. 2009;30:526–33. http://dx.doi.org/10.1086/597507

Address for correspondence: David H. Smith, The Center for Health Research, Kaiser Permanente Northwest, 3800 N. Interstate Ave, Portland, OR 97227, USA; email: david.h.smith@kpchr.org

Like our podcasts?
Sign up to receive email announcements when a new podcast is available.

www.cdc.gov/ncidod/eid/subscribe.htm